The immunomodulatory parasitic worm product ES-62 reduces lupus-associated accelerated atherosclerosis in a mouse model.

Tamar R. Aprahamian, Xuemei Zhong, Shahzada Amir, Christoph J. Binder, Lo-Ku Chiang, Lamyaa Al-Riyami, Raffi Gharakhanian, Margaret M. Harnett, William Harnett, Ian R. Rifkin

Research output: Contribution to journalArticle

16 Citations (Scopus)
45 Downloads (Pure)

Abstract

ES-62 is an anti-inflammatory phosphorylcholine-containing glycoprotein secreted by the filarial nematode Acanthocheilonema viteae. Accelerated atherosclerosis frequently occurs in systemic lupus erythematosus, resulting in substantial cardiovascular morbidity and mortality. We examined the effects of ES-62 in the gld.apoE(-/-) mouse model of this condition. Treatment with ES-62 did not substantially modulate renal pathology but caused decreased anti-nuclear autoantibody levels. Moreover, a striking 60% reduction in aortic atherosclerotic lesions was observed, with an associated decrease in macrophages and fibrosis. We believe that these latter findings constitute the first example of a defined parasitic worm product with therapeutic potential in atherosclerosis: ES-62-based drugs may represent a novel approach to control accelerated atherosclerosis in systemic lupus erythematosus.
Original languageEnglish
Pages (from-to)203-207
Number of pages5
JournalInternational Journal for Parasitology
Volume45
Issue number4
Early online date7 Feb 2015
DOIs
Publication statusPublished - 1 Mar 2015

Fingerprint

Helminths
Atherosclerosis
Systemic Lupus Erythematosus
Acanthocheilonema
Phosphorylcholine
Apolipoproteins E
Autoantibodies
Glycoproteins
Fibrosis
Anti-Inflammatory Agents
Macrophages
Pathology
Morbidity
Kidney
Mortality
Pharmaceutical Preparations
Therapeutics

Keywords

  • atherosclerosis
  • ES-62
  • helminth
  • systemic lupus erythematosus

Cite this

Aprahamian, Tamar R. ; Zhong, Xuemei ; Amir, Shahzada ; Binder, Christoph J. ; Chiang, Lo-Ku ; Al-Riyami, Lamyaa ; Gharakhanian, Raffi ; Harnett, Margaret M. ; Harnett, William ; Rifkin, Ian R. / The immunomodulatory parasitic worm product ES-62 reduces lupus-associated accelerated atherosclerosis in a mouse model. In: International Journal for Parasitology. 2015 ; Vol. 45, No. 4. pp. 203-207.
@article{9b8d37039e434c17be0852c6abeab79c,
title = "The immunomodulatory parasitic worm product ES-62 reduces lupus-associated accelerated atherosclerosis in a mouse model.",
abstract = "ES-62 is an anti-inflammatory phosphorylcholine-containing glycoprotein secreted by the filarial nematode Acanthocheilonema viteae. Accelerated atherosclerosis frequently occurs in systemic lupus erythematosus, resulting in substantial cardiovascular morbidity and mortality. We examined the effects of ES-62 in the gld.apoE(-/-) mouse model of this condition. Treatment with ES-62 did not substantially modulate renal pathology but caused decreased anti-nuclear autoantibody levels. Moreover, a striking 60{\%} reduction in aortic atherosclerotic lesions was observed, with an associated decrease in macrophages and fibrosis. We believe that these latter findings constitute the first example of a defined parasitic worm product with therapeutic potential in atherosclerosis: ES-62-based drugs may represent a novel approach to control accelerated atherosclerosis in systemic lupus erythematosus.",
keywords = "atherosclerosis, ES-62, helminth, systemic lupus erythematosus",
author = "Aprahamian, {Tamar R.} and Xuemei Zhong and Shahzada Amir and Binder, {Christoph J.} and Lo-Ku Chiang and Lamyaa Al-Riyami and Raffi Gharakhanian and Harnett, {Margaret M.} and William Harnett and Rifkin, {Ian R.}",
year = "2015",
month = "3",
day = "1",
doi = "10.1016/j.ijpara.2014.12.006",
language = "English",
volume = "45",
pages = "203--207",
journal = "International Journal for Parasitology",
issn = "0020-7519",
number = "4",

}

Aprahamian, TR, Zhong, X, Amir, S, Binder, CJ, Chiang, L-K, Al-Riyami, L, Gharakhanian, R, Harnett, MM, Harnett, W & Rifkin, IR 2015, 'The immunomodulatory parasitic worm product ES-62 reduces lupus-associated accelerated atherosclerosis in a mouse model.', International Journal for Parasitology, vol. 45, no. 4, pp. 203-207. https://doi.org/10.1016/j.ijpara.2014.12.006

The immunomodulatory parasitic worm product ES-62 reduces lupus-associated accelerated atherosclerosis in a mouse model. / Aprahamian, Tamar R.; Zhong, Xuemei; Amir, Shahzada; Binder, Christoph J.; Chiang, Lo-Ku; Al-Riyami, Lamyaa; Gharakhanian, Raffi; Harnett, Margaret M.; Harnett, William; Rifkin, Ian R.

In: International Journal for Parasitology, Vol. 45, No. 4, 01.03.2015, p. 203-207.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The immunomodulatory parasitic worm product ES-62 reduces lupus-associated accelerated atherosclerosis in a mouse model.

AU - Aprahamian, Tamar R.

AU - Zhong, Xuemei

AU - Amir, Shahzada

AU - Binder, Christoph J.

AU - Chiang, Lo-Ku

AU - Al-Riyami, Lamyaa

AU - Gharakhanian, Raffi

AU - Harnett, Margaret M.

AU - Harnett, William

AU - Rifkin, Ian R.

PY - 2015/3/1

Y1 - 2015/3/1

N2 - ES-62 is an anti-inflammatory phosphorylcholine-containing glycoprotein secreted by the filarial nematode Acanthocheilonema viteae. Accelerated atherosclerosis frequently occurs in systemic lupus erythematosus, resulting in substantial cardiovascular morbidity and mortality. We examined the effects of ES-62 in the gld.apoE(-/-) mouse model of this condition. Treatment with ES-62 did not substantially modulate renal pathology but caused decreased anti-nuclear autoantibody levels. Moreover, a striking 60% reduction in aortic atherosclerotic lesions was observed, with an associated decrease in macrophages and fibrosis. We believe that these latter findings constitute the first example of a defined parasitic worm product with therapeutic potential in atherosclerosis: ES-62-based drugs may represent a novel approach to control accelerated atherosclerosis in systemic lupus erythematosus.

AB - ES-62 is an anti-inflammatory phosphorylcholine-containing glycoprotein secreted by the filarial nematode Acanthocheilonema viteae. Accelerated atherosclerosis frequently occurs in systemic lupus erythematosus, resulting in substantial cardiovascular morbidity and mortality. We examined the effects of ES-62 in the gld.apoE(-/-) mouse model of this condition. Treatment with ES-62 did not substantially modulate renal pathology but caused decreased anti-nuclear autoantibody levels. Moreover, a striking 60% reduction in aortic atherosclerotic lesions was observed, with an associated decrease in macrophages and fibrosis. We believe that these latter findings constitute the first example of a defined parasitic worm product with therapeutic potential in atherosclerosis: ES-62-based drugs may represent a novel approach to control accelerated atherosclerosis in systemic lupus erythematosus.

KW - atherosclerosis

KW - ES-62

KW - helminth

KW - systemic lupus erythematosus

UR - http://www.sciencedirect.com/science/article/pii/S002075191500020X

U2 - 10.1016/j.ijpara.2014.12.006

DO - 10.1016/j.ijpara.2014.12.006

M3 - Article

VL - 45

SP - 203

EP - 207

JO - International Journal for Parasitology

JF - International Journal for Parasitology

SN - 0020-7519

IS - 4

ER -